Egypt Pharmaceuticals and Healthcare Report Q3 2014

Date: June 18, 2014
Pages: 125
Price:
US$ 1,295.00
Publisher: Business Monitor International
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E868351A17DEN
Leaflet:

Download PDF Leaflet

Includes 3 FREE quarterly updates

BMI View: The landslide victory by Abdel Fattah al-Sisi in the presidential election in Egypt increases the attractiveness of the country's pharmaceutical market, which has been deteriorating for the past few years. Key challenges facing multinational companies include a restrictive medicine pricing regime, a lack of regulatory data protection and poor patent enforcement. Domestic companies are meanwhile impaired by a weakened currency, which restricts their ability to import raw materials for manufacturing pharmaceuticals.

Headline Expenditure Projections

Pharmaceuticals: EGP14.34bn (USD2.09bn) in 2013 to EGP15.89bn (USD2.27bn) in 2014; +10.8% in local currency terms and 8.7% in US dollar terms. Forecast revised downwards since Q314, due deterioration in intellectual property regime.
BMI Industry View
SWOT
Political
Economic
Business Environment
Industry Forecast
Pharmaceutical Market Forecast
  Table: Pharmaceutical Sales, Historical Data And Forecasts (Egypt 2010-2018)
Healthcare Market Forecast
  Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2010-2018)
  Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2010-2018)
  Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2010-2018)
Prescription Drug Market Forecast
  Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Egypt 2010-2018)
Patented Drug Market Forecast
  Table: Patented Drug Market Indicators, Historical Data And Forecasts (Egypt 2010-2018)
Generic Drug Market Forecast
  Table: Generics Drug Market Indicators, Historical Data And Forecasts (Egypt 2010-2018)
OTC Medicine Market Forecast
  Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Egypt 2010-2018)
Pharmaceuticals Trade Forecast
  Table: Pharmaceutical Trade Data And Forecasts (Egypt 2012-2018)
  Table: Pharmaceutical Trade Data And Forecasts local currency (Egypt 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Macroeconomic Forecasts
Economic Analysis
  Table: Egypt - Gdp By Expenditure
Industry Risk Reward Ratings
Middle East & Africa Risk/Reward Ratings
Egypt Risk/Reward Ratings
Rewards
Risks
Market Overview
Industry Trends And Developments
Epidemiology
Communicable Diseases
Non-Communicable Disease
Healthcare Sector
Private Healthcare Sector
Healthcare Financing
Healthcare Insurance
Research & Development
Clinical Trials
Regulatory Development
Medicines Registration
Regional Harmonisation
Counterfeit Medicines
Intellectual Property
Pricing Regime
Reimbursement Regime
Watch List Status
Competitive Landscape
Pharmaceutical Industry
  Table: HOLDIPHARMA's Joint Ventures, 2012
Domestic Pharmaceuticals Sector
  Table: HOLDIPHARMA's Affiliated Companies, 2012
  Table: HOLDIPHARMA's Financial Indicators, FY 2006/2007-FY2010/2011 (EGPmn)
  Table: HOLDIPHARMA's Net Operating Revenue by Affiliate, FY 2010/2011 (EGPmn)
  Table: Wholly Or Partially Owned Egyptian Pharmaceutical And Medical Device Companies By Parent Group
Foreign Pharmaceuticals Sector
Recent Industry Developments
Pharmaceutical Wholesale
Pharmaceutical Retail
Herbal And OTC Medicine
Company Profile
Egyptian International Pharmaceutical Industries Co (EIPICO)
South Egyptian Drug Industries (SEDICO)
Medical Union Pharmaceuticals (MUP)
Amoun Pharmaceutical Company (APC)
VASCERA
Misr Pharmaceuticals
GlaxoSmithKline
Sanofi
Pfizer
Novartis
Merck
AstraZeneca
Demographic Forecast
  Table: Egypt's Population By Age Group, 1990-2020 ('000)
  Table: Egypt's Population By Age Group, 1990-2020 (% of total)
  Table: Egypt's Key Population Ratios, 1990-2020
  Table: Egypt's Rural And Urban Population, 1990-2020
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Ratings Overview
  Table: Pharmaceutical Risk/Reward Ratings Indicators
Indicator Weightings
Egypt Pharmaceuticals and Healthcare Report Q1 2014 US$ 1,295.00 Dec, 2013 · 130 pages
Egypt Pharmaceuticals and Healthcare Report Q2 2014 US$ 1,295.00 Mar, 2014 · 124 pages
OTC Healthcare in Egypt to 2014 US$ 495.00 Jul, 2010 · 170 pages
Algeria Pharmaceuticals and Healthcare Report Q2 2014 US$ 1,295.00 Feb, 2014 · 105 pages
Belgium Pharmaceuticals and Healthcare Report Q4 2013 US$ 1,295.00 Sep, 2013 · 107 pages

Ask Your Question

Egypt Pharmaceuticals and Healthcare Report Q3 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: